You are here

Home » Content

Artralji Yakınmalı Multiple Sklerosis Hastalarında Serum Human Parvovirus B19 Seropozitifliği

Human Parvovirus B19 Seroposıtivity in Multiple Sclerosis Patients With Arthralgia

Journal Name:

  • Fırat Tıp Dergisi

Publication Year:

  • 2004

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objectives: The aim of this study is to investigate human parvovirus B19 (HPV B19) seropositivity in the multiple sclerosis (MS) patients with widespread arthralgia complaint. Material & methods: The study group consisted of 23 patients with relapsing-remitting MS (RR-MS), not receiving interferon treatment for prophylactic purpose, having an Extended Disability Status Score (EDSS) less than 3 and having no local or systemically diseases which may lead to arthralgia. The control group consisted of 21 cases matched according to age and sex. The levels of anti-HPV IgG and IgM were examined in sera of patients and control groups. Results: The levels of anti-HPV IgG and IgM in sera were not differing significantly between the patients with MS versus control group. Conclusion: Although anti-HPV B19 IgG and IgM antibody levels were higher in MS patients, this difference between MS and control groups was not statistically significant. ©2004, Fırat Üniversitesi, Tıp Fakültesi
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Çalışmamızda yaygın artralji şikayeti olan multiple skleroz (MS) hastalarında serum Human Parvovirus B 19 ( HPV) seropositifliğini araştırmayı amaçladık. Gereç ve Yöntem: Hasta grubu relapsing-remitting multiple skleroz (RR-MS) tanısı alan ve herhangi bir koruyucu tedavi almayan ve Extended Disability Status Score (EDSS) 3 den az olan 23 kişiden oluşturuldu. Bu hastaların tümünde artralji şikayeti mevcuttu ve artralji yapabilecek sistemik ve lokal bir hastalık saptanmamıştı. Kontrol grubu yaş ve cinsiyet uyumlu 21 kişiden oluşturuldu. Hasta ve kontrol grubunun serumlarında anti-HPV IgG ve IgM seviyeleri ölçüldü. Bulgular ve Sonuç: Hasta ve kontrol grubu serumlarında anti-HPV IgG ve IgM seviyeleri arasında istatistiksel olarak bir anlamlılık saptanmadı. Yaygın artralji şikayeti olan RR-MS hasta grubunda serum anti-HPV IgG ve IgM seviyeleri kontrol grubuna göre daha yüksek düzeylerde bulunmasına karşın istatistiksel olarak bir anlamlılık saptanmadı. ©2004, Fırat Üniversitesi, Tıp Fakültesi
FULL TEXT (PDF): 
PDF icon arastirmax-artralji-yakinmali-multiple-sklerosis-hastalarinda-serum-human-parvovirus-b19-seropozitifligi.pdf
  • 4
127-129
  • Turkish

REFERENCES

References: 

1. Miyamoto K, Ogami M, Takahashi Y et al. Outbreak of human parvovirus B19 in hospital workers. J Hosp Infect 2000; 45: 238¬41.
2. Barah F, Vallely PJ, Cleator GM et al. Neurological manifestations of human parvovirus B19 infection. Rev Med
Virol 2003; 13: 185-99.
3. Lehmann HW, von Landenberg P, Modrow S. Parvovirus B19 infection and autoimmune disease. Autoimmun Rev 2003; 2: 218¬23
4. Woolf AD, Campion GV, Chishick A et al. Clinical
manifestations of human parvovirus B19 in adults. Arch Intern Med 1989; 149: 1153-56.
5. Kerr JR. Parvovirus B19 infection. Eur J Clin Microbiol Infect
Dis 1996; 15:10-29
6. Nocton JJ, Miller LC, Tucker LB et al. Human parvovirus B19-
associated arthritis in children. J Pediatr 1993; 122: 186-90.
7. Soderlund M, von Essen R, Haapasaari J et al. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropaty. Lancet 1997; 12: 1063-5.
8. Cassinotti P, Burtonboy G, Fopp M et al. Evidence for persistence of human parvovirus B19 DNA in bone marrow. J
Med Virol 1997; 53: 229-32.
9. Eis-Hubinger AM, Reber U, Abdul-Nour T et al. Evidence for persistence of parvovirus B19 DNA in livers of adults. J Med
Virol 2001; 65: 395-401.
10. Lehmann HW, Kuhner L, Beckenlehner K et al. Chronic human parvovirus B19 infection in rheumatic disease of childhood and adolescence. J Clin Virol 2002; 25: 135 -43.
11. Naides SJ, Scharosch LL, Foto F et al. Rheumatologic manifestations of human parvovirus B19 infection in adults. Initial two-year clinical experience. Arthritis Rheum 1990; 33:
1297 -309.
12. Stahl HD, Seidl B, Hubner B et al. High incidence of parvovirus B19 DNA in synovial tissue of patients with undifferentiated
mono-and oligoarthritis. Clin Rheumatol 2000; 19: 281 -6.
13. Mitchell LA. Parvovirus B19 nonstructural (NS1) protein as a transactivator of interleukin-6 synthesis: common pathway in inflammatory sequelae of human parvovirus infections? J Med
Virol 2002; 67: 267-74
14. Hayakawa H, Tara M, Niina K et al. A clinical study of adult human parvovirus B19 infection. Intern Med 2002: 41: 295-9
15. 15. Munschauer FE 3rd, Kinkel RP. Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Ther 1997 ; 19: 883-93.
16. Yamashita K, Matsunaga Y, Taylor Y et al. A significant age shift of the human parvovirus B19 antibody prevalence among young adults in Japan observed in a decade. Jpn J Med Sci Biol
1992; 45: 49-58.
17. Nakashima I, Fujihara K, Itoyama Y. Human parvovirus B19 infection in multiple sclerosis. Eur Neurol 1999; 42: 36-40.

Thank you for copying data from http://www.arastirmax.com